L-121-2022
Agreement ID
L-121-2022
Lead IC
NIAID
Exclusivity
Nonexclusive
External Party
Medicines Patent Pool Foundation
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-3420 Structure-Based Design of SARS-CoV-2 Spike Immunogens Stabilized in the RBD-All Down Conformation
TAB-4075 RNASEH-Assisted Detection Assay for RNA
TAB-4042 Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method
TAB-4955 SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies
TAB-3449 Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use
TAB-3427 High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid
TAB-3430 A VSV-EBOV-Based Vaccine Against COVID-19
TAB-3439 Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS-CoV-2 Spike and Its Use
TAB-4075 RNASEH-Assisted Detection Assay for RNA
TAB-4042 Sensitive and Economic RNA Virus Detection Using a Novel RNA Preparation Method
TAB-4955 SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies
TAB-3449 Recombinant Chimeric Bovine/Human Parainfluenza Virus 3 Expressing SARS-CoV-2 Spike Protein and Its Use
TAB-3427 High-Throughput COVID-19 Diagnostic Test that Detects Both Viral and Host Nucleic Acid
TAB-3430 A VSV-EBOV-Based Vaccine Against COVID-19
TAB-3439 Newcastle Disease Virus-Like Particle Displaying Prefusion Stabilized SARS-CoV-2 Spike and Its Use